Peptide-Targeted Radiation Therapy Works Well for Korean Neuroendocrine Tumor Patients, Matching Western Trial Results
Lu-177 DOTATATE peptide receptor radionuclide therapy in 64 Korean patients with advanced neuroendocrine tumors achieved 21.7 months median progression-free survival and 20% response rate, consistent with the landmark NETTER-1 trial.
Quick Facts
What This Study Found
Lu-177 DOTATATE PRRT in Korean NET patients achieved median PFS of 21.7 months, 20% ORR, and 88% one-year OS, with significantly better outcomes in grade 1-2 versus grade 3 tumors (HR 3.15, p=0.006).
Key Numbers
Korean patients with advanced NETs. Lu-177 PRRT evaluated for efficacy and safety.
How They Did This
Retrospective study of 64 patients treated with Lu-177 DOTATATE PRRT at Asan Medical Center, Seoul, between November 2019 and December 2022. Evaluated PFS, OS, ORR, and safety. Median follow-up: 15.7 months.
Why This Research Matters
Confirming that peptide receptor radionuclide therapy works equally well in Asian patients addresses a significant evidence gap. This gives Korean and other Asian oncologists confidence in offering this treatment and helps establish local treatment protocols.
The Bigger Picture
Peptide receptor radionuclide therapy represents one of the most successful applications of peptide targeting in oncology. This study extends the evidence base to an underrepresented population and reinforces Lu-177 DOTATATE as a global standard of care for advanced somatostatin receptor-positive NETs.
What This Study Doesn't Tell Us
Retrospective design without a control group. Single-center study from a major academic hospital, which may not represent all Korean treatment centers. Median OS not reached due to relatively short follow-up. Combined heterogeneous NET primary sites and grades.
Questions This Raises
- ?Are there pharmacogenomic differences that affect PRRT efficacy or toxicity in Asian versus Western patients?
- ?What is the optimal sequencing of PRRT relative to other NET treatments in Korean patients?
- ?Could earlier use of PRRT (before 2 prior therapy lines) improve outcomes further?
Trust & Context
- Key Stat:
- 21.7-month median PFS In Korean NET patients receiving Lu-177 DOTATATE PRRT, consistent with the NETTER-1 trial results
- Evidence Grade:
- Moderate evidence from a real-world retrospective cohort. Results consistent with the randomized NETTER-1 trial, strengthening confidence in the findings despite the retrospective design.
- Study Age:
- Published in 2024, using data from 2019-2022. Represents the most current Korean real-world PRRT data available.
- Original Title:
- Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
- Published In:
- Targeted oncology, 19(1), 41-49 (2024)
- Authors:
- Shin, Yeokyeong(2), Moon, Bo Hyun, Ryoo, Baek-Yeol(2), Chang, Heung-Moon, Kim, Kyu-Pyo, Hong, Yong Sang, Kim, Tae Won, Ryu, Jin-Sook, Kim, Yong-Il, Yoo, Changhoon
- Database ID:
- RPEP-09259
Evidence Hierarchy
Frequently Asked Questions
How does peptide receptor radionuclide therapy work?
Lu-177 DOTATATE is a radioactive peptide that binds to somatostatin receptors, which are abundant on neuroendocrine tumor cells. Once bound, it delivers targeted radiation directly to the tumor while largely sparing surrounding healthy tissue.
What are the main side effects of this treatment?
The most common side effects are blood count changes (anemia, low white cells, low platelets), which occurred at serious levels in 8-11% of patients. These are generally manageable and consistent with what's seen in Western studies. No unexpected safety signals were found.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-09259APA
Shin, Yeokyeong; Moon, Bo Hyun; Ryoo, Baek-Yeol; Chang, Heung-Moon; Kim, Kyu-Pyo; Hong, Yong Sang; Kim, Tae Won; Ryu, Jin-Sook; Kim, Yong-Il; Yoo, Changhoon. (2024). Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.. Targeted oncology, 19(1), 41-49. https://doi.org/10.1007/s11523-023-01022-z
MLA
Shin, Yeokyeong, et al. "Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.." Targeted oncology, 2024. https://doi.org/10.1007/s11523-023-01022-z
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radi..." RPEP-09259. Retrieved from https://rethinkpeptides.com/research/shin-2024-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.